Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer
JY Wu, JY Shih, CH Yang, KY Chen… - … journal of cancer, 2010 - Wiley Online Library
Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC).
However, after failure of gefitinib, it is unknown whether any second‐line regimens could …
However, after failure of gefitinib, it is unknown whether any second‐line regimens could …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …